FinBoss.io
CSEN
  • Crypto prices
  • Liquidation War
  • Crypto tools
  • Bitcoin on-chain
  • US macro
  • US stocks
    • Largest US stocks
    • Stock screener
    • Earnings calendar
    • Insider trading
    • Market heatmap
  • Markets
  • Tools
  • Guides
  • FinBot
FinBoss.io
Crypto prices
Liquidation War
Crypto tools
Altcoin Season Index
Big players (on-chain)
Bitcoin halving countdown
Bear market radar
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Largest US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Markets
Stock indices
Commodities
Forex rates
Bear market radar
Famous investors' portfolios
Tools
Dashboards
Investor dashboardTrader dashboardBeginner dashboard
Calculators
Compound interestDCA calculatorDrawdown recovery
Compare
BrokersCrypto exchanges
Přehled sekce Tools →
Guides
FinBot
CSEN
Home
Stocks
West Pharmaceutical Svsc Inc
WS

West Pharmaceutical Svsc Inc

WSTNASDAQ

Stock · Data from SEC EDGAR 13F · Held by 13 of 87 tracked investors

$398.29
▲ 0.90%
Famous investorshold 13buying 1selling 0
Price (USD)
$398.29
Market cap
$28B
P/E ratio
51
Tracked investors holding
13 of 87
Next earnings
29 Oct 2026

West Pharmaceutical Svsc Inc at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
69out of 100
  • Valuation20
  • Growth53
  • Profitability78
  • Quality80
  • Debt100
  • Stability83
In its favour
  • ✓Out of 100 USD of revenue, 17 USD is left as net profit.
  • ✓It earns 19 USD a year on every 100 USD of invested capital (ROE).
  • It has more cash than debt.

Is the stock expensive?

Expensive

For 1 USD of annual earnings you pay 51.0 USD. Based on next year's estimates 39.9 USD.

P/E
51.0×
P/S
8.4×
EV/EBITDA
30.3×

Is the company growing?

Growing slowly
22
23
24
25

Revenue over 3 years grew 2.1% a year. Last year 13.8%.

Does it make money?

Good

Revenue and net profit (USD B)

Margins (% of revenue)

Free cash flow and capex (USD B)

Cash and debt (USD B)

Earnings per share (EPS, USD)

Latest quarters (USD B)

Chart WST

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

13
BG
Bill Gates
Gates Foundation Trust
0.46%$159,575,500unchanged
SC
Steven Cohen
Point72 Asset Management
0.11%$101,739,164▲ +77.8%
RB
Ron Baron
Baron Capital
0.09%$58,938,466▼ -17.8%
Šn
Švýcarská národní banka
Swiss National Bank
0.04%$72,934,440▼ -3.8%
Čn
Česká národní banka
Česká národní banka
0.04%$7,497,138▲ +0.6%
Ns
Norský státní fond
Norges Bank
0.03%$309,786,485New position
RD
Ray Dalio
Bridgewater Associates
0.02%$3,744,011▼ -55%
JS
Jim Simons
Renaissance Technologies
0.02%$11,093,100▼ -85.3%
JG
Joel Greenblatt
Gotham Asset Management
0.01%$4,344,259▲ +71.3%
KG
Ken Griffin
Citadel Advisors
0.01%$126,644,071▲ +9%
CA
Cliff Asness
AQR Capital Management
0.01%$20,330,740▼ -78.4%
PT
Paul Tudor Jones
Tudor Investment Corp
0.01%$8,562,509▼ -63.5%
KF
Ken Fisher
Fisher Investments
0%$237,546▼ -96.5%

Frequently asked questions

How much is West Pharmaceutical Svsc Inc (WST) stock?

West Pharmaceutical Svsc Inc shares trade at $398.29, +0.90% over the last trading day. The price is delayed.

What is the market cap of West Pharmaceutical Svsc Inc?

The market cap of West Pharmaceutical Svsc Inc is about $28B and its price-to-earnings ratio (P/E) is 51.

Which big investors hold West Pharmaceutical Svsc Inc?

According to the latest 13F filings, 13 of 87 tracked investors hold West Pharmaceutical Svsc Inc, for example Bill Gates, Steven Cohen, Ron Baron.

When will West Pharmaceutical Svsc Inc report its next results?

The next earnings report of West Pharmaceutical Svsc Inc is expected on 29 Oct 2026.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms of usePrivacy policyCookie policy

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

✓
  • ✓It pays a 0.3% dividend, which takes 11% of earnings.
  • What to watch
    • !Revenue grew only 2.1% a year over 3 years.
    • !The stock is expensive: you pay 51 USD for 1 USD of annual earnings.

    The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

    • Cost of sales 64
    • Research 2.4
    • Operations and selling 12.8
    • Taxes and other 4.6
    • Net profit 16.1

    Out of 100 USD of revenue, 16.1 USD is left as net profit.

    Is it financially healthy?

    Yes
    Cash
    436M USD
    Debt
    317M USD
    Free CF
    278M USD

    It has more cash than debt.

    Does it pay a dividend?

    Pays
    Yield
    0.26%
    Of earnings
    11%

    Over a year you receive roughly 0.26% of the price per share. The payout is manageable for the company. It has raised the dividend for 8 years in a row.

    What do analysts expect?

    Strong buy
    Average target
    416.40 USD
    Vs price
    +5%

    15 analysts. Their opinion is not a recommendation by FinBoss.io.

    Which big investors hold it?

    13 of 87

    Among the tracked investors, Bill Gates, Steven Cohen, Ron Baron and others hold the stock according to 13F filings.

    Dividend per share by year (USD)

    * the year has not ended yet. Source: Yahoo Finance.

    Ratios

    P/E
    51.0×
    Forward P/E
    39.9×
    P/B
    9.4×
    P/S
    8.4×
    PEG
    3.07
    EV/EBITDA
    30.3×
    Gross margin
    36.8%
    Operating margin
    22.5%
    Net margin
    17.0%
    ROE
    19.1%
    ROA
    11.4%
    Debt / equity
    0.1×
    Current ratio
    2.8×
    Revenue growth
    13.8%
    Earnings growth
    18.1%
    Beta
    1.13
    Dividend
    0.26%
    Payout ratio
    11%